MCMary J. Choi

Mary J. Choi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mary J. Choi has a total of 181 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Investigation of Dinga Dinga: A Cluster of Bilateral Lower-Extremity Tremors—Bundibugyo District, Uganda, 2023–2024

    by Sophia Mulei, Daniel Orit, Mary J. Choi, Shannon Whitmer, Katrin S. Sadigh, Jimmy Baluku, Kami Smith, Alison Todres, Calvin R. Torach, Benigna Namara, et al.

    : In September 2023, a cluster of unexplained illness in women affecting their ability to stand/walk was reported at Bundibugyo Hospital, Uganda. Field investigations were conducted to verify reports, conduct active case finding, and identify potential causes using a hypothesis-generating questionnaire, a neurological examination tool, and a standardized laboratory panel. As of January 31, 2025, 136 patients were identified; all were female. Among 108 with age data, the median age was 18 years old, and all but one lived in Bundibugyo District. All reported bilateral lower-extremity tremors interfering with their ability to stand/walk that resolved when sitting or lying down. Of 75 women evaluated, 33 (44%) were acutely symptomatic at assessment. Tremors lasted between 4 days and 3 months. Of 90 women who provided symptom recurrence information, 20 (22%) reported recurrent episodes. No shared environmental exposures of concern were identified among 76 patients with data. Although limited female-specific exposures were noted, no known toxins were identified among patients. Blood specimens were submitted for laboratory testing, and 24 of 93 (26%) tested positive for Plasmodium . One of 34 (3%) tested positive for Shigella spp. Three of 87 (3%) were positive for Ekpoma virus 2 (EKV2), and 41 of 80 (51%) were anti-EKV2 IgG positive. Metagenomic sequencing confirmed two of the EKV2 cases and identified rickettsiae-specific reads in one individual. It is still unknown whether the cause is an infectious agent or an environmental toxin. This outbreak highlights the importance of strong field epidemiology and laboratory capacity in investigating emerging neurological syndromes.

  • Case Series of Patients With Laboratory-Confirmed Marburg Virus Disease in 2023 in Equatorial Guinea

    by Florentino Abaga Ondo Ndoho, Luca Fontana, Candido Ondo Ondo Avomo, Ladislao Ekiri Ngomo Mikue, Domitila Ñadang Fuga Eyemam, Micaela Ayang Nguere, Ilda Elobe Mometolo, Rosalia Nazang Bibang Nzang, Damaso Mitogo Nguema Maye, Yosbanis Hernandez Suarez, et al.

    Background: Marburg virus disease (MVD) is a severe viral infection caused by the Marburg marburgvirus species. In February 2023, Equatorial Guinea declared its first outbreak. This case series describes the natural history of MVD in 5 patients with laboratory-confirmed disease. Methods: Patients with confirmed MVD who were admitted to the national treatment center in Bata, Equatorial Guinea were monitored for vital signs and symptoms. Comprehensive clinical data were collected to understand the progression and outcome of the disease. Results: Five patients were confirmed to have MVD. Three male healthcare workers received a diagnosis diagnosed early in their disease and subsequently survived. The other 2 patients, both female, were admitted later in their disease progression and died within 24 hours of admission. Four patients received remdesivir under a protocol for the monitored emergency use of unregistered and experimental interventions. The early symptoms were nonspecific, with rapid progression to more severe conditions in the later stages of the disease. Early treatment with remdesivir showed the drug to be well tolerated. Conclusions: Contrary to some reports and the recommended case definition for MVD, our patients presented with a rash but did not exhibit vomiting or diarrhea. Hemorrhagic signs were solely observed in the terminal stage, preceding demise. Despite the limited sample size, these findings emphasize the importance of tailoring the case definition to the specific outbreak. Further evidence on the efficacy and safety of therapeutics for MVD, including remdesivir, should be gathered through well-designed trials during future epidemic responses.


  • Open Access

    Ebola virus disease nosocomial infections in the Democratic Republic of the Congo: a descriptive study of cases during the 2018–2020 outbreak

    by April Baller, Maria Clara Padoveze, Patrick Mirindi, Carmen Emily Hazim, Jonathan Lotemo, Jerome Pfaffmann, Aminata Ndiaye, Simone Carter, Marie-Amelie Degail Chabrat, Samuel Mangala, et al.


  • Open Access

    Development and implementation of the Ebola Exposure Window Calculator: A tool for Ebola virus disease outbreak field investigations

    by Amy Whitesell, Nirma D. Bustamante, Miles Stewart, Jeff Freeman, Amber M. Dismer, Walter Alarcon, Aaron Kofman, Amen Ben Hamida, Stuart T. Nichol, Inger Damon, et al.

    During an Ebola virus disease (EVD) outbreak, calculating the exposure window of a confirmed case can assist field investigators in identifying the source of infection and establishing chains of transmission. However, field investigators often have difficulty calculating this window. We developed a bilingual (English/French), smartphone-based field application to assist field investigators in determining the exposure window of an EVD case. The calculator only requires the reported date of symptoms onset and the type of symptoms present at onset or the date of death. Prior to the release of this application, there was no similar electronic capability to enable consistent calculation of EVD exposure windows for field investigators. The Democratic Republic of the Congo Ministry of Health endorsed the application and incorporated it into trainings for field staff. Available for Apple and Android devices, the calculator continues to be downloaded even as the eastern DRC outbreak resolved. We rapidly developed and implemented a smartphone application to estimate the exposure window for EVD cases in an outbreak setting


  • Open Access

    Chainchecker: An application to visualise and explore transmission chains for Ebola virus disease

    by Katy Gaythorpe, Aaron Morris, Natsuko Imai, Miles Stewart, Jeffrey Freeman, Mary Choi

    2020 saw the continuation of the second largest outbreak of Ebola virus disease (EVD) in history. Determining epidemiological links between cases is a key part of outbreak control. However, due to the large quantity of data and subsequent data entry errors, inconsistencies in potential epidemiological links are difficult to identify. We present chainchecker, an online and offline shiny application which visualises, curates and verifies transmission chain data. The application includes the calculation of exposure windows for individual cases of EVD based on user defined incubation periods and user specified symptom profiles. It has an upload function for viral hemorrhagic fever data and utility for additional entries. This data may then be visualised as a transmission tree with inconsistent links highlighted. Finally, there is utility for cluster analysis and the ability to highlight nosocomial transmission. chainchecker is a R shiny application which has an offline version for use with VHF (viral hemorrhagic fever) databases or linelists. The software is available athttps://shiny.dide.imperial.ac.uk/chaincheckerwhich is a web-based application that links to the desktop application available for download and the github repository,https://github.com/imperialebola2018/chainchecker.


  • Use of Ebola Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020

    by Mary J. Choi, Caitlin M. Cossaboom, Amy N. Whitesell, Jonathan W. Dyal, Allison Joyce, Rebecca L. Morgan, Doug Campos-Outcalt, Marissa Person, Elizabeth Ervin, Yon C. Yu, et al.

    Summary of the Advisory Committee on Immunization Practices’ recommendations for use of Ebola vaccine in the United States.

  • Open Access

    A Case of Lassa Fever Diagnosed at a Community Hospital—Minnesota 2014

    by Mary J Choi, Shewangizaw Worku, Barbara Knust, Arnold Vang, Ruth Lynfield, Mark R Mount, Tina Objio, Shelley Brown, Jayne Griffith, Deborah Hulbert, et al.

    Background: In April 2014, a 46-year-old returning traveler from Liberia was transported by emergency medical services to a community hospital in Minnesota with fever and altered mental status. Twenty-four hours later, he developed gingival bleeding. Blood samples tested positive for Lassa fever RNA by reverse transcriptase polymerase chain reaction. Methods: Blood and urine samples were obtained from the patient and tested for evidence of Lassa fever virus infection. Hospital infection control personnel and health department personnel reviewed infection control practices with health care personnel. In addition to standard precautions, infection control measures were upgraded to include contact, droplet, and airborne precautions. State and federal public health officials conducted contract tracing activities among family contacts, health care personnel, and fellow airline travelers. Results: The patient was discharged from the hospital after 14 days. However, his recovery was complicated by the development of near complete bilateral sensorineural hearing loss. Lassa virus RNA continued to be detected in his urine for several weeks after hospital discharge. State and federal public health authorities identified and monitored individuals who had contact with the patient while he was ill. No secondary cases of Lassa fever were identified among 75 contacts. Conclusions: Given the nonspecific presentation of viral hemorrhagic fevers, isolation of ill travelers and consistent implementation of basic infection control measures are key to preventing secondary transmission. When consistently applied, these measures can prevent secondary transmission even if travel history information is not obtained, not immediately available, or the diagnosis of a viral hemorrhagic fever is delayed.


  • Open Access

    The Effects of an Integrated Community Case Management Strategy on the Appropriate Treatment of Children and Child Mortality in Kono District, Sierra Leone: A Program Evaluation

    by Ruwan Ratnayake, Jeffrey Ratto, Colleen Hardy, Curtis Blanton, Laura Miller, Mary Choi, John Kpaleyea, Pheabean Momoh, Yolanda Barbera

    Integrated community case management (iCCM) aims to reduce child mortality in areas with poor access to health care. iCCM was implemented in 2009 in Kono district, Sierra Leone, a postconflict area with high under-five mortality rates (U5MRs). We evaluated iCCM’s impact and effects on child health using cluster surveys in 2010 (midterm) and 2013 (endline) to compare indicators on child mortality, coverage of appropriate treatment, timely access to care, quality of care, and recognition of community health workers (CHWs). The sample size was powered to detect a 28% decline in U5MR. Clusters were selected proportional to population size. All households were sampled to measure mortality and systematic random sampling was used to measure coverage in a subset of households. We used program data to evaluate utilization and access; 5,257 (2010) and 3,649 (2013) households were surveyed. U5MR did not change significantly (4.54 [95% confidence interval [CI]: 3.47–5.60] to 3.95 [95% CI: 3.06–4.83] deaths per 1,000 per month (P = 0.4)) though a relative change smaller than 28% could not be detected. CHWs were the first source of care for 52% (2010) and 50.9% (2013) of children. Coverage of appropriate treatment of fever by CHWs or peripheral health units increased from 45.5% [95% CI: 39.2–52.0] to 58.2% [95% CI: 50.5–65.5] (P = 0.01); changes for diarrhea and pneumonia were not significant. The continued reliance on the CHW as the first source of care and improved coverage for the appropriate treatment of fever support iCCM’s role in Kono district.


  • Open Access

    Screening of genital fluid for Ebola virus – Authors' reply

    by Moses J Soka, Mary J Choi, Lawrence J Purpura, Ute Ströher, Barbara Knust, Pierre Rollin


  • Zika virus in semen: lessons from Ebola

    by Lawrence J Purpura, Mary J Choi, Pierre E Rollin